SUMMARY
INTRODUCTION
The interleukin (IL)-16 gene, located on chromosome 15, and formerly known as lymphocyte chemoattractant factor, is produced by activated CD8 + T lymphocytes.
1,2 IL-16 functions as a chemoattractant for CD4
+ T cells, 3, 4 eosinophils, 5 monocytes, 3 bronchial epithelial cells 6 and macrophages. 2 IL-16 has been shown to up-regulate IL-2 receptor (IL-2R or CD25) 3, 7 and induce the transient loss of responsiveness via the T-cell receptor (TCR). This multifunctional cytokine and its precursor (pro-IL-16) have been detected in various tissues and in peripheral blood mononuclear cells (PBMC). 8 IL-16 is synthesized in the form of pro-IL-16 with an apparent molecular weight of 80 000. 9 Studies suggest that pro-IL-16 is proteolytically cleaved intracellularly to form peptides of 14±17 kDa prior to secretion. 8 However, for biological function, these peptides multimerize to form 56-kDa homotetramers. Western blot analysis with antibodies to the 14-kDa protein enabled identi®cation of an 80-kDa protein, suggesting the presence of pro-IL-16. 8, 9 Although IL-16 appears to autoaggregate to form bioactive multimers, 8 the mechanism of IL-16 secretion remains uncertain. IL-16 does not appear to have any homology with any previously described cytokines. 10 The role of IL-16 in diseases is characterized by CD4 + T-cell involvement, as observed in multiple sclerosis, 11 ,12 asthma 4,13 and acquired immune de®-ciency syndrome (AIDS). 14±16 Besides its function as a chemoattractant, IL-16 is also known as a modulator of T-cell activation and as a potential inhibitor of human immunode®-ciency virus-1 (HIV-1) replication. 14, 15, 17 Given the pivotal role of this cytokine in AIDS, de®ning cellular distributions of IL-16 will enhance our understanding of IL-16 production and secretion. In this report we demonstrate that tumour-derived human B-cell lines express IL-16 mRNA ubiquitously and secrete IL-16 protein, irrespective of whether or not these cells have integrated Epstein±Barr virus (EBV) genome.
MATERIALS AND METHODS

Cell lines
The study included 13 tumour B-cell lines derived from patients with undifferentiated lymphomas of Burkitt's and nonBurkitt's origin, as described previously. 18 The characteristics of these cells are summarized in Table 1 . Five of these cell lines ± 10C9, 2F7, HBL-1, HBL-2 and HBL-3 ± are AIDSassociated B-cell lines (AABCL). 10C9 is an EBV + human B-cell line established from a non-Hodgkin's lymphoma patient with AIDS. 2F7 is also EBV + , and was established from a Burkitt's lymphoma patient with AIDS. HBL-1, HBL-2 and HBL-3 were derived from patients with AIDS-associated lymphomas and were a kind gift from Dr Riccardo DallaFavera (Columbia University, NY). HBL-1 is EBV + , whereas HBL-2 and HBL-3 are EBV ± . 19 HIV-1 viral sequences were not detected in any of these cell lines. The non-AABCLs comprised ®ve EBV ± American Burkitt's lymphoma cell lines: BJAB, EW36, CA46, ST486 and MC116; and three EBV + African Burkitt's lymphoma cell lines: Raji, Namalva and Daudi. Establishment of the B-cell lines, together with their phenotypic characteristics, have been reported previously. 18, 20, 21 All cell lines were maintained in suspension culture in RPMI-1640 containing 10% fetal calf serum (FCS) (Cellgro; Fisher Scienti®c, Pittsburgh, PA) at 37u in a 5% CO 2 humidi®ed atmosphere.
Exposure of cells to phorbol 12-myristate 13-acetate Cells obtained on day 4 of subculture were resuspended in fresh medium at a cell density of 1r10 6 cells/ml. The cells were incubated in 75-cm 2 tissue culture¯asks at 37u for various lengths of time in the presence or absence of the tumour promoter phorbol 12-myristate 13-acetate (PMA; Sigma Chemical Co., St Louis, MO). A wide range of PMA concentrations (5±100 ng/ml) was studied, and optimal results were obtained at a concentration of 10 ng/ml. Control and PMA-activated cultures were harvested at designated timepoints, and the cells were immediately processed for RNA isolation. The supernatants were collected and stored at x80u until assayed for IL-16 secretion. Total cellular RNA was extracted from control and PMA-activated cells using guanidinium isothiocyanate±phenol chloroform, as described previously. 18, 20, 21 Reverse transcription±polymerase chain reaction (RT±PCR) analysis for detection of interleukin-16 transcript Using a Perkin-Elmer PE2400 Thermal Cycler (Perkin-Elmer Foster City, CA), cDNAs were prepared by reverse transcription (RT) of 1 mg of total RNA, as previously described.
18,20±23
Brie¯y, 5 ml of the cDNA sample was ampli®ed with 2 . 5 U of Taq DNA polymerase (Fisher). The reaction mixture consisted of 20 pmol of each of the sense and antisense primers in PCR buffer, 2 mM MgCl 2 and 200 mM each of dATP, dCTP, dGTP and dTTP. The mixture was ampli®ed over 30 cycles. The ®rst two cycles consisted of denaturation at 97u for 1 min, primer annealing at 60u for 1 min, and primer extension at 72u for 1 min. An additional 28 cycles of denaturation at 94u for 1 min were followed with similar annealing and primer extension conditions as used in the ®rst two cycles. A ®nal extension was performed at 72u for 7 min, followed by storage at 4u. Primers were designed based on the sequence published by Baier et al.
14
Speci®c primers for the upper and lower strands consisted of bp 789±808: 5k-GACCTCAACTCCTCCACTGA-3k; and bp 1111±1130: 5k-CTCCTGATGACAATCGTGAC-3k, respectively. Primers were custom made by Bioserve (Laurel, MD) and were used to amplify a 341-bp region of the IL-16 transcript. The housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was ampli®ed concurrently with IL-16 using the same RT mixture. The primers used for GAPDH ampli®cation have been published previously.
18,20±23 The amplicons were detected by ethidium bromide staining after electrophoresis through 2% Tris-borate/EDTA agarose gels. Semiquanti®cation of relative intensities of the PCR amplicons was performed using the Collage 3 . 0 intensity scanning function (Macintosh, Apple Computer Inc., Cupertino, CA). Intensity readings were quanti®ed by comparing the IL-16 expression levels with those of GAPDH.
Cloning and sequencing of RT±PCR products
The 341-bp amplicons of IL-16 and 358-bp sequence of GAPDH from two representative cell lines, HBL-1 and Raji, were subcloned into the dephosphorylated HincII site of the pBluescript II plasmid vector (Stratagene, La Jolla, CA), following modi®cation with T4 DNA polymerase to remove the 3k non-template-directed base addition, as previously described.
18,20±23 Brie¯y, the blunt-end amplicons were treated with T4 polynucleotide kinase and ligated into the vector using T4 DNA ligase at 12u overnight. After transformation of competent bacteria, white colonies growing in Luria±Bertani medium (LB) agar containing 100 mg/ml of ampicillin, 40 mg/ml of isopropylthio-b-D-galactoside and 40 mg/ml of 5-bromo-4-chloro-3-inodyl-b-D-galactoside, were selected and grown in 5 ml of Terri®c Broth with 100 mg/ml of ampicillin. Plasmid mini preparations were performed by alkaline lysis of 1 . 5 ml of the overnight culture. Plasmids containing the appropriate size inserts, as determined by electrophoresis through 1 . 5% Trisacetate/EDTA agarose after restriction digestion, were sequenced using the Applied Biosystems Sequencer model 373A (Applied Biosystems, Foster City, CA).
IL-16 enzyme-linked immunosorbent assay (ELISA)
Supernatants obtained from control and PMA-activated cells were collected and 100 ml of the supernatant was assayed. After normalizing for equal amounts of protein, secreted IL-16 was detected using the Cytoscreen immunoassay kit (BioSource International, Camarillo, CA), following the manufacturer's guidelines. This kit recognizes both precursor and mature forms of IL-16. The minimum detectable dose, without apparent cross-reactivity to various cytokines and adhesion molecules, was <5 pg/ml, as outlined by the manufacturer.
RESULTS
Detection of the IL-16 transcript by using RT±PCR
The HBL-1 cell line was used as a representative B-cell line to study the kinetics of IL-16 mRNA transcripts and secretion from 1 to 96 hr in culture. HBL-1 cells obtained on day 3 after subculture were resuspended at a concentration of 5r10 5 cells/ml in fresh medium containing 10% FCS and incubated at 37u with and without PMA for 1, 3, 5, 8, 24, 48, 72 and 96 hr. At each time-point, the culture was harvested for RNA isolation, and the supernatants were collected for ELISA. As shown in Fig. 1(a) , constitutive IL-16 transcripts were expressed from 1 hr with a peak accumulation at 24 hr. Furthermore, mitogen stimulation augmented mRNA expression by < onefold, as compared to untreated control cells, at each time-point. To ensure that the differences seen in mRNA expression at these time-points were not caused by variations in PCR ef®ciency or relative amounts of amplicon products, but indeed re¯ected changes in IL-16 kinetics, these expressions were normalized to that of GAPDH and repeated several times. the constitutive secretion of IL-16 was detected as early as 1 hr, increased secretion in control and PMA-stimulated cells was observed from the 24 hr time-point onwards.
Having identi®ed the optimal time-point for IL-16 expression and secretion as 24 hr in the representative HBL-1 cell line, we performed RT±PCR analysis several times on constitutive and PMA-induced expression of IL-16 in all the other B-cell lines. All the 13 cell lines (Table 1) expressed IL-16 mRNA transcript constitutively, as shown in Fig. 2 . However, upon mitogen stimulation in the AABCLs (Fig. 2a) , a twofold increase in IL-16 expression was observed in 10C9, no change in 2F7, HBL-1 or HBL-3 and a fourfold increase in HBL-2. 
Cloning and sequencing IL-16 and GAPDH RT-PCR products
We cloned and sequenced the 341-bp amplicons of IL-16, and the 358-bp of GAPDH, from two representative cell lines, HBL-1 and Raji. The IL-16 sequence was identical to the sequence reported previously by Baier et al. 14 The GAPDH sequence was identical to sequence previously described 18,20±23 (data not shown).
Il-16 ELISA
Secretion of IL-16 was quanti®ed using standard IL-16 protein provided by the manufacturer (BioSource). Least-square-®t linear regression analysis was performed on the absorbance value measured by using an EL309 microplate autoreader (Bio-Tek Instruments, Winooski, VT), and the results are summarized in Table 2 . We did not observe any speci®c patterns of IL-16 secretion between AABCLs, EBV ± nonAABCLs and EBV + non-AABCLs at the 24 hr time-point. The data, as shown in Table 2 , suggests heterogeneity in IL-16 secretion.
DISCUSSION
Studies of the role that B cells play in pathogenesis have identi®ed several important cytokines, such as IL-10, IL-7, IL-12 and macrophage in¯ammatory protein-1a (MIP-1a), some of which are secreted in an autocrine manner. 18, 20, 21, 24 These ®ndings suggest that modulation of viral expression may be in¯uenced by some of these regulatory cytokines. In addition, some of the soluble factors secreted by B cells may, in fact, have suppressive effects on viral replication. Although B cells are not natural targets for HIV, their transformation with EBV may cause expression of the CD4 molecule, thus facilitating viral infection. 25 The binding of IL-16 to CD4 results in activation of p56 lck , the function of which is essential for the chemotactic response. 26 Zhou et al. demonstrated that transfection of CD4 + Jurkat cells with IL-16 dramatically reduced the expression of HIV-1 tat and rev transcripts, as analysed by RT±PCR analysis. 17 To determine whether IL-16 mRNA is modulated by HIV-1 tat, RT±PCR analysis was performed on HIV-1 tat-transfected Bcell (Raji-tat) and T-cell (Jurkat-tat) lines. The Jurkat-tat cell line was obtained from The AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH (Bethesda, MD; donated by Drs A. Caputo, W. Haseltine and J. Sodroski) and the Raji-tat cell line was a gift from Dr J. Sodroski (Dana Farber Cancer Institute, Boston, MA). The Raji-tat and Jurkat-tat cell lines were used in a previous study on cytokine modulation of HIV-1 tat transfection. 23 In a later work, no dramatic changes were observed with regard to IL-16 mRNA expression or secretion, either constitutively or with PMA induction, as compared to non-transfected Jurkat or Raji control cells (data not shown).
Several exciting features can be deduced from the results of the present work. IL-16 expression and secretion has been demonstrated for the ®rst time in tumour-derived human B-cell lines. It is tempting to speculate that the histology and tissue source of these cell lines may be attributed to the heterogeneous expression and secretion of IL-16. EBV ± B-cell lines are generally not known for their cytokine production, 18, 20, 21 with the exception of MC116 for MIP-1a. 18 However, we observed expression and secretion of IL-16 mRNA in all EBV ± cell lines. To conclude, the recognition that B cells are a source of IL-16 adds to the cytokines known to be formed by this class of lymphocytes.
